Sabari Examines Frontline and Second-Line Treatment Options in NSCLC

May 24, 2020

Joshua K. Sabari, MD, goes through treatment options in the frontline and second-line for patients with non–small cell lung cancer in a Targeted Oncology case-based peer perspectives live discussion.

Neoadjuvant Atezolizumab With Chemotherapy Feasible in Advanced NSCLC

May 24, 2020

"Our trial, together with ongoing randomized trials, provides more evidence on the risks and benefits of immunotherapy as a neoadjuvant treatment, and could help to answer questions regarding the optimal duration, best surrogate endpoint, and best predictive biomarkers for treatment."

Gerber Addresses the Role of Mutations and Treatment in NSCLC at Different Stages

May 23, 2020

In a Targeted Oncology case-based peer perspectives live discussion, David Gerber, MD, addresses the role of biomarkers in guiding treatment decisions for patients with non–small cell lung cancer based on a patient scenario.

Immunotherapy-Based Combos May be Necessary in Neuroendocrine Neoplasms

May 22, 2020

The immune checkpoint inhibitor induced 1 objective response but appeared safe as treatment of patients with metastatic high-grade neuroendocrine neoplasms in 2 open-label phase 2 clinical trials.

Trending News on Targeted Oncology, Week of May 22, 2020

May 22, 2020

Targeted Oncology reviews trending news online for the week of May 22, 2020, including recent news from the FDA, updates in oncology, and new information regarding COVID-19.

FDA Approves Brigatinib as Frontline Treatment of ALK-Positive Metastatic NSCLC

May 22, 2020

The FDA has granted approval to brigatinib for the frontline treatment of patients with ALK-positive metastatic non–small cell lung cancer, as detected by an FDA-approved test.

Older Patients With Triple-Negative Breast Cancer Should Be Assessed Different for Treatment

May 22, 2020

Enrique Soto Pérez de Celis, MD, MSc, explains that although geriatric patients with breast cancer can be treated similarly to their younger counterparts, more steps are involved in the treatment decision-making process, starting with appropriate assessment of the patient.

Trastuzumab Deruxtecan Receives Orphan Drug Designation from FDA for Gastric Cancer

May 22, 2020

Fam-trastuzumab deruxtecan-nxki has received an Orphan Drug designation for the treatment of patients with gastric or gastroesophageal junction cancer.

Medical Meeting Planners Pivot to Share Advances With the Oncology

May 22, 2020

"We will continue to find innovative ways to come together both in person and virtually to more widely disseminate valuable information regarding important advances in cancer research."

Patients in CheckMate 067 Demonstrate Durable Complete Responses

May 22, 2020

Georgina V. Long, BSc, PhD, MBBS, discusses the response rates in the CheckMate 067 trial, which evaluated the combination of ipilimumab and nivolumab in patients with advanced melanoma.